H.R. 9830 Is the Off-Ramp: Inside the Lawful Hemp Protection Act

The Lawful Hemp Protection Act is no longer a rumor, draft, or talking point. H.R. 9830 was introduced in the House on July 22, 2026, by Rep. Andy Barr of Kentucky with Rep. Angie Craig of Minnesota as the original Democratic cosponsor. Its basic wager is direct: Congress can protect adults and children with real product rules without pushing most cannabinoid hemp outside the federal definition of hemp.

Legal research checked: July 31, 2026, 4:19 p.m. EDT.

That distinction matters. H.R. 9830 has been introduced and referred to four House committees. It has not passed the House. It has not passed the Senate. It has not been signed. It does not yet change anyone's legal obligations.

But it is the most detailed legislative off-ramp now sitting between today's hemp framework and the federal change scheduled for November 12, 2026.

Quick-answer Q&A

Q: What is the biggest change H.R. 9830 would make?

A: It would repeal Section 781 of P.L. 119-37 and replace the scheduled definition-based restrictions with a national system for adult-only sales, domestic sourcing, product testing, labels, cannabinoid limits, permits, taxes, enforcement, and state authority.

Q: Would H.R. 9830 guarantee that every THCA or hemp THC product stays legal?

A: No. The bill creates new exclusions and compliance duties, and states could remain stricter. A specific product would still need to satisfy the final enacted text, future agency rules, and applicable state and local law.

Q: Did the bill already move the November 12, 2026 deadline?

A: No. Introduced legislation does not alter an enacted effective date. The Section 781 baseline remains scheduled unless Congress passes and the president signs a change.

Q: Why is H.R. 9830 more significant than a simple delay bill?

A: Delay bills create more time. H.R. 9830 attempts the harder job of designing the long-term federal market that would exist after the delay: who can participate, what can be sold, how it must be tested and labeled, and how violations are enforced.

The status in 30 seconds

• Bill: H.R. 9830, the Lawful Hemp Protection Act
• Sponsor: Rep. Andy Barr (R-KY-6)
• Introduced: July 22, 2026
• Original cosponsor: Rep. Angie Craig (D-MN-2)
• New cosponsors: Rep. Tim Moore (R-NC-14) and Rep. Marc Veasey (D-TX-33), added July 30
• Current total: three cosponsors, in addition to the sponsor
• Committees: House Ways and Means; Energy and Commerce; Agriculture; Transportation and Infrastructure
• Latest action reviewed: committee referrals on July 22
• Current stage: Introduced

That is movement, not victory. Cosponsors can signal widening support, but only enacted text changes federal law.

Why H.R. 9830 exists

The pressure comes from Section 781 of Public Law 119-37. Signed on November 12, 2025, that enacted provision rewrites the federal definition of hemp one year after enactment.

Among other changes, the new definition uses total THC rather than delta-9 THC alone and excludes a final hemp-derived cannabinoid product when it contains more than 0.4 milligrams combined total per container of total THC and certain cannabinoids with similar effects. The Congressional Research Service says products pushed outside the hemp definition may instead fall under federal Controlled Substances Act treatment as marijuana or regulated THC when the change takes effect.

The key date is November 12, 2026.

That is the baseline unless Congress enacts something else. Introduced bills do not pause the clock.

H.R. 9830 would take a different route. Section 3 would repeal Section 781 and replace it with a much larger federal system governing cultivation, manufacturing, testing, labeling, sales, taxation, permitting, beverage distribution, and interstate movement.

In plain English: the bill does not ask Washington to ignore the hemp market. It asks Washington to regulate it.

The first major shift: a 1% total-THC plant definition

The introduced text would define hemp as Cannabis sativa L. and its naturally occurring derivatives with no more than 1% total THC, including THCA, on a dry-weight basis. It would explicitly include industrial hemp and create a separate category for unfinished hemp-cannabinoid ingredients moving between permitted commercial actors.

That unfinished-ingredient category is important. Manufacturing does not happen in one clean jump from plant to final package. Oils, extracts, concentrates, and distillates can temporarily exceed the plant threshold during processing. H.R. 9830 would allow that material to move only between licensed or otherwise permitted actors, bar retail sale of the unfinished ingredient, and require further processing into a finished product.

The proposal is not a free-for-all. It excludes cannabinoids that cannot be naturally produced by cannabis and targets certain chemical conversions. The text specifically names HHC, THC-O-acetate, and THCP when produced through covered artificial modification, while authorizing additional determinations by the Agriculture and Health and Human Services secretaries.

That approach tries to draw a line between naturally occurring hemp chemistry and deliberately altered analogs. Whether every technical definition lands perfectly is exactly the kind of issue the committee process should test in public.

Adult-only sales become a federal rule

H.R. 9830 would make the sale of a hemp-derived cannabinoid product to anyone under 21 a prohibited act under the Federal Food, Drug, and Cosmetic Act. It would also prohibit possession or consumption by a person under 21.

That is a bright national floor. States could remain stricter.

The bill also attacks youth-directed presentation. A covered product could be deemed misbranded when its package imitates imagery associated with children's marketing. It expressly calls out characters, animals, vehicles, cartoons, candy, fruit, and brightly colored products or packaging.

The objective is easy to understand: adult products should look like adult products. The execution will need precision. A rule broad enough to treat any fruit reference or bright color as youth targeting could sweep farther than intended, so FDA definitions and enforcement guidance would matter.

That is not an argument for doing nothing. It is an argument for writing the rule well.

Labels would have to do real work

Under the introduced bill, the front panel would have to disclose milligrams of THC per serving and per package and state that the product is for users 21 and older. The label would also have to address serving size, servings per package, ingredients, cannabinoid content, allergens where required, intended human or animal use, and risks for specific populations.

Other provisions require warnings related to pregnancy and impaired driving, disclosure of drug-testing risk, and a disclaimer that FDA has not found the product safe or effective for treating a condition.

A QR code or other scannable mechanism would need to connect consumers with additional product information. The bill also prohibits false or misleading advertising and bars structure-or-function claims for covered products.

This is the opposite of hiding behind a vague botanical label. It turns the package into an accountability surface.

Testing moves from a promise to a rule

The bill directs the HHS secretary to establish uniform manufacturing and testing requirements for finished and intermediate hemp-derived cannabinoid products. Those requirements must address key components, potential contaminants, and cannabinoid content.

Testing would be required at two meaningful points:

• after post-harvest processing, extraction, or another manipulation identified by the secretary; and
• in the final form offered to the consumer.

The laboratory would have to be accredited to ISO/IEC 17025. The government could inspect records needed to determine compliance.

That creates an enforceable chain instead of a one-time marketing certificate. It also recognizes a basic quality fact: a test on incoming plant material cannot, by itself, prove the composition or cleanliness of a finished formulation.

FDA would set product limits—and the bill supplies a backstop

H.R. 9830 gives FDA 12 months after enactment to establish maximum total-cannabinoid and individual-cannabinoid amounts per product and per serving. The agency would use notice-and-comment rulemaking informed by peer-reviewed research, adverse-event and usage data, medical and scientific input, state regulatory experience, product form, intended use, and the target consumer population.

If FDA misses the deadline, statutory fallback limits would apply until the agency acts:

• 5 milligrams total THC per serving for orally consumed products;
• 50 milligrams per serving for inhalable products; and
• 50 milligrams per serving for topical products.

Those numbers deserve serious technical review. Milligrams in an inhalable or topical format do not necessarily map cleanly to the consumer experience of an ingestible. Still, the architecture is notable: a deadline, a public rulemaking process, product-form distinctions, and a fallback designed to prevent agency inaction from freezing the entire framework.

Domestic sourcing is built into the market

The introduced bill would prohibit interstate introduction of a hemp-derived cannabinoid product unless it is derived exclusively from hemp cultivated in the United States, processed in the United States, and finished, packaged, and labeled in the United States.

That is an industrial-policy choice as much as a consumer rule. It connects federal market access to a domestic chain of custody and gives regulators clearer jurisdiction over the actors involved.

It also raises practical questions. Companies would need reliable provenance records, manufacturers would need to audit suppliers, and regulators would need definitions for what counts as processing, finishing, and repackaging. If Congress adopts a domestic-only rule, traceability cannot be an afterthought.

Permits, taxes, and a three-tier beverage system

H.R. 9830 reaches beyond FDA. It creates a Treasury permitting structure for manufacturers of hemp-derived cannabinoid products and wholesalers of hemp-derived beverages. It also establishes operational records, inventories, enforcement tools, civil penalties, criminal penalties for fraudulent conduct, and judicial review.

The tax structure is substantial:

• hemp-derived beverages would face a federal excise tax of 5 cents per milligram of THC;
• other hemp-derived cannabinoid products would face a tax equal to 5% of the manufacturer's sale price; and
• manufacturers would also face a separate annual tax equal to 5% of sales revenue.

The beverage provisions borrow from alcohol's three-tier logic by separating manufacturers, wholesalers, and retailers and restricting tied-house practices. Supporters see that as a proven accountability model. Critics will reasonably ask whether the taxes layer cleanly, whether smaller operators can absorb the compliance burden, and whether the distribution system fits every state market.

Those questions belong in hearings, markups, and economic analysis—not in a last-minute cliff.

States keep power, but compliant transit gets protection

The bill preserves state, territorial, and Tribal authority to impose rules that are more stringent than the federal floor or at least as protective as a comparable alcohol system. At the same time, it would prevent those jurisdictions from blocking the passage and delivery of compliant products through their borders.

That balance matters. A national rule should not automatically erase a state's decision to be stricter. But a lawful shipment should not become contraband merely because the truck crosses a jurisdiction where the product is not sold.

The proposal tries to protect both regulatory federalism and the physical integrity of interstate commerce.

What H.R. 9830 does not do

The bill does not legalize marijuana. It does not prevent states from restricting or prohibiting hemp-derived cannabinoid sales. It does not guarantee that any specific product would qualify under future FDA limits. It does not make today's labels, tests, formulas, or supply chains automatically compliant.

Most importantly, it does not take effect merely because it has bipartisan sponsors.

To become law, H.R. 9830 must move through committee, pass the House, pass the Senate in identical form, and be signed by the president—or clear a veto. Its text can also be amended at any stage.

Do not confuse H.R. 9830 with the Comer draft

Rep. James Comer of Kentucky is also reported to be circulating a separate, seven-page hemp proposal. Marijuana Moment reported on July 29 that the draft would delay the Section 781 restrictions until one year after FDA supplies the required cannabinoid lists and container guidance. The reported draft also includes 21-and-older sales, U.S. sourcing, naturally producible cannabinoids, child-resistant packaging, testing, good manufacturing practices, and QR-linked laboratory results.

As of this research timestamp, that Comer proposal had not been formally filed, according to the report, and we did not locate an introduced bill number in the official congressional record reviewed.

That makes it a policy draft, not an introduced bill and certainly not a law. If a formal version is filed, the introduced text—not the circulated draft—will become the controlling source for our coverage.

The Illest read: this is a serious off-ramp, not a finished product

The 0.4-milligram rule is a classification cutoff. H.R. 9830 is a regulatory system.

One tells the market what cannot remain hemp. The other tries to answer the harder questions: Who may sell? To what age? With which tests? Under what labels? From what supply chain? At what limits? With which permits and penalties?

That is why this bill deserves immediate, transparent committee work. Congress should not confuse flaws in an unregulated corner of the marketplace with proof that regulation cannot work. Nor should the hemp industry treat the word regulation as betrayal. A durable adult market requires enforceable standards, meaningful testing, accurate labels, consequences for bad actors, and rules that can survive scrutiny.

H.R. 9830 is ambitious and imperfect. Its tax layering, product-form fallback limits, marketing definitions, technical cross-references, and compliance costs all deserve hard questions. The November deadline does not justify skipping that work. It makes the work urgent.

What happens next

Watch the official Congress.gov record for H.R. 9830, not rumor alone. The signals that would materially change the bill's status include:

• a committee hearing or markup;
• an amended or committee-reported version;
• a House floor vote;
• a Senate companion or Senate action;
• incorporation into a larger legislative vehicle;
• passage in identical form by both chambers; and
• presidential signature.

Two new cosponsors joined on July 30. That is worth tracking. It is not a substitute for the steps above.

Readers who want to advocate can review the U.S. Hemp Roundtable action page and contact their elected representatives. Read the official text first. Be specific about the rules you support and the provisions you want improved.

For the whole federal timeline—including P.L. 119-37, H.R. 7010, and S. 3686—read the Illest Haze federal THCA and hemp tracker.

Frequently asked questions

Is the Lawful Hemp Protection Act law?

No. H.R. 9830 is at the Introduced stage. It has been referred to four House committees and has not passed either chamber.

Did H.R. 9830 stop the November 12, 2026 change?

No. The enacted baseline remains in place unless Congress enacts a change. H.R. 9830 proposes to repeal Section 781, but a proposal has no legal effect by itself.

Is H.R. 9830 bipartisan?

Yes in sponsorship: Republican Rep. Andy Barr introduced it with Democratic Rep. Angie Craig as an original cosponsor. Republican Rep. Tim Moore and Democratic Rep. Marc Veasey were added as cosponsors on July 30.

Does the bill allow every hemp cannabinoid product now sold?

No. It excludes covered synthetic or artificially modified cannabinoids, imposes adult-only sales, creates labeling and testing duties, establishes future product limits, requires domestic sourcing, and allows stricter state rules.

Is the Comer proposal the same bill?

No. H.R. 9830 is Barr's introduced bill. Comer's reported proposal is a separate circulated draft and did not have a formal bill number as of this research timestamp.

Primary and supporting sources

• Congress.gov: H.R. 9830 all information and actions
• Congress.gov: H.R. 9830 introduced text
• Congressional Research Service: Changes to the Statutory Definition of Hemp and Issues for Congress
• Congressional Research Service: Changes to the Federal Definition of Hemp—Legal Considerations
• Rep. Andy Barr: official introduction release
• Marijuana Moment: reporting and draft link for the separate Comer proposal

Legal notice: This article provides general information and editorial analysis, not legal advice. Hemp and cannabinoid rules can differ by product, conduct, date, state, Tribe, territory, and locality. Consult qualified counsel and current official sources for a specific situation.